Published by Independent Med Management (IMM)  |  Reading time: 7 minutes

Opioid dependency is one of the most significant clinical and financial challenges in Workers’ Compensation. What begins as appropriate short-term pain management can evolve over months into long-term prescribing with diminishing clinical benefit and increasing harm. Understanding how to safely reduce and cease opioid use, and who should be involved, is critical knowledge for claims managers, case managers, and treating clinicians.

Why Opioids Become Problematic in WC Claims

Opioids are legitimately prescribed for acute pain following injury. The problem arises when short-term prescribing extends into the sub-acute and chronic phases without reassessment. Multiple Australian and international guidelines note that opioids provide limited benefit for chronic non-cancer pain, particularly musculoskeletal conditions, which represent the majority of WC injury types.

Long-term opioid use in WC claims is associated with:

• Delayed functional recovery and return to work
• Opioid-induced hyperalgesia, where the medication actually increases pain sensitivity
• Cognitive impairment affecting safety-critical work roles
• Physical dependency requiring careful medical management to cease
• Psychological dependency and associated mental health comorbidities
• Significantly elevated claim costs over the life of the claim

When Should Opioid Reduction Be Considered?

A structured opioid reduction plan is appropriate when one or more of the following applies:

• Opioids have been prescribed for more than 90 days for a non-cancer pain condition
• The claimant’s functional capacity has not improved despite opioid use
• Dose escalation has occurred without corresponding functional improvement
• The morphine equivalent daily dose (MEDD) exceeds 90mg, a threshold associated with significantly elevated risk
• There are signs of dependency, aberrant medication-taking behaviours, or diversion risk
• Return to work is being delayed by sedation, cognitive effects, or opioid-related impairment
• A medication review has identified opioids as high-risk or clinically unjustified

The Principles of Safe Opioid Tapering in Australia

Australian clinical guidelines, including those from the Agency for Clinical Innovation (ACI), RACGP, and the University of Sydney Deprescribing Guidelines, outline a consistent framework for opioid tapering. The core principles are as follows.

Gradual, Not Abrupt

Abrupt opioid cessation is rarely appropriate outside of acute overdose management. Sudden withdrawal is distressing and increases the risk of relapse. Australian guidelines recommend a gradual reduction, typically 5 to 20 percent of the total daily dose per month, adjusted based on the individual’s response.

Slow Taper for Long-Term Use

Claimants who have been on opioids for more than 12 months require particularly slow tapering. A reduction of 5 to 10 percent every two to three weeks is appropriate for this group. The longer the duration of use and the higher the dose, the more cautiously the taper should proceed.

Individualised Approach

No two claimants will tolerate the same tapering schedule. Plans should be reviewed regularly and the rate of reduction paused or reversed if the claimant experiences severe withdrawal symptoms, significant deterioration in pain control, or acute psychological distress. The goal is sustained reduction, not speed.

Consolidation to a Single Opioid

Where a claimant is taking multiple opioid medications, best practice is to consolidate to a single long-acting formulation before commencing the taper. This simplifies dose management and gives the prescriber precise control over the rate of reduction.

Who Should Be Involved?

Opioid tapering in a WC claim is not a task for any single clinician or stakeholder. Best outcomes are achieved through a coordinated, multidisciplinary approach.

The Treating GP

The GP manages the taper in practice: writing prescriptions, adjusting doses, monitoring for withdrawal, and managing non-opioid pain alternatives. However, GPs often need clinical support to initiate a taper, particularly if the prescribing was initiated by a specialist or has been ongoing for an extended period.

Independent Clinical Pharmacist

An independent pharmacy review, such as those provided by IMM, gives the GP a detailed, evidence-based assessment of the claimant’s full medication regime and a recommended tapering plan. With an 81% prescriber implementation rate, IMM’s recommendations are acted on in the vast majority of cases. The pharmacist can also communicate directly with the GP to address any clinical questions about the proposed plan.

Pain Specialist or Addiction Medicine Physician

For high-complexity cases, referral to a pain specialist or addiction medicine physician is appropriate. These specialists can manage buprenorphine-assisted tapering, residential withdrawal programs, or complex cases where the treating GP requires specialist support.

Psychologist or Counsellor

Psychological support is a critical component of opioid tapering for claimants with concurrent mental health conditions, catastrophising, or pain-related anxiety. Cognitive behavioural therapy for chronic pain and acceptance and commitment therapy have strong evidence bases and should be integrated into the broader return-to-work plan.

Case Manager

The case manager plays a coordinating role: ensuring referrals are made, reports are shared with treating clinicians, and the return-to-work plan accounts for the tapering timeline. Case managers should not be directing clinical decisions but should be actively engaged in the governance of the process.

Non-Pharmacological Pain Management

Opioid tapering is far more likely to succeed when alternatives are in place. Non-pharmacological strategies with evidence support for musculoskeletal pain include:

• Physiotherapy and graded exercise programs
• Pain neuroscience education
• Cognitive behavioural therapy for chronic pain
• Acceptance and commitment therapy
• Hydrotherapy for lower limb and back injuries
• Occupational therapy for functional restoration

These interventions should be introduced early in the tapering process, not after opioids have been ceased. The goal is to build the claimant’s capacity to manage pain without relying on opioids before the medication is reduced.

The Role of an IMM Pharmacy Review

Arranging an independent pharmacy review through IMM is frequently the most efficient way to initiate an opioid reduction process in a WC claim. A review provides:

• A clear clinical rationale for reduction that is defensible and evidence-based
• A proposed tapering schedule tailored to the claimant’s current dose and duration of use
• Identification of other medications that may need to be adjusted as opioids are reduced
• A report that the GP can use as a framework for the tapering conversation with the claimant
• Optional direct pharmacist-to-GP communication to support implementation

Key Australian Resources

The following resources are useful for clinicians, case managers, and claimants navigating opioid reduction:

• NPS MedicineWise: 5 Steps to Tapering Opioids. A structured clinical tool for GPs.
• University of Sydney: Guidelines on Safer Opioid Deprescribing. Developed with specialist input.
• TGA Clinician Information Sheet: Specific tapering protocols and regulatory guidance.
• Agency for Clinical Innovation (ACI): Clinical resources for pain management in NSW.
• Painaustralia: Consumer and clinician resources for chronic pain management.

Summary

Opioid deprescribing in Workers’ Compensation requires a planned, gradual, multidisciplinary approach. It should be initiated as early as clinically appropriate, supported by non-pharmacological pain management, and governed by a clear tapering plan that the treating GP can implement with confidence.

An IMM pharmacy review is the most direct way to generate a defensible clinical rationale and a practical tapering plan within the WC context. With an 81% prescriber implementation rate, the evidence is clear: good pharmacy reviews change clinical practice.

Independent Med Management (IMM) provides pharmacy review and medication risk governance services to Workers’ Compensation and CTP insurers across Australia. This article is for general information purposes. Clinical decisions should be made in consultation with qualified health professionals.